Jun 09 2020 Relmada Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference View
May 27 2020 Relmada Therapeutics Announces Outcome of End-of-Phase 2 Meeting with FDA for REL-1017 for Adjunctive Treatment of Patients with Major Depressive Disorder View
May 26 2020 Relmada Therapeutics Appoints Molly Harper as Executive Vice President of Operations View
Apr 28 2020 Relmada Therapeutics Enhances Senior Leadership Team with Appointment of Brian A. Walter, Ph.D., as Vice President of Regulatory Affairs View
Mar 31 2020 Relmada Therapeutics Solidifies its R&D Leadership Team with the Appointment of Marc de Somer, MD, MBA, ScD, MPH, MSc, as Senior Vice President, Clinical Development and Safety View
Mar 24 2020 Relmada Therapeutics Strengthens Scientific Leadership Team with the Appointment of Judy Caron, Ph.D., as Vice President of Drug Development View
Mar 09 2020 Relmada Therapeutics Appoints CNS Specialist Thomas C. Wessel, M.D., Ph.D., as Executive Vice President, Head of Research and Development View
Feb 25 2020 Relmada Therapeutics to Present at 9th Annual SVB Leerink Global Healthcare Conference View
Jan 10 2020 Relmada Therapeutics Strengthens Financial Operations with Addition of Maged Shenouda as Chief Financial Officer View
